Literature DB >> 9334312

The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity.

S T Wen1, R A Van Etten.   

Abstract

Biochemical and genetic evidence suggests that the tyrosine kinase activity of c-Abl is tightly regulated in vivo by a cellular factor binding to the Src homology 3 (SH3) domain of Abl. We used the yeast two-hybrid system to identify a gene, PAG, whose protein product (Pag) interacts specifically with the Abl SH3 domain. Pag, also known as macrophage 23-kD stress protein (MSP23), is a member of a novel family of proteins with antioxidant activity implicated in the cellular response to oxidative stress and in control of cell proliferation and differentiation. In a co-expression assay, Pag associates with c-Abl in vivo and inhibits tyrosine phosphorylation induced by overexpression of c-Abl. Inhibition requires the Abl SH3 and kinase domains and is not observed with other Abl SH3-binding proteins. Expression of Pag also inhibits the in vitro kinase activity of c-Abl, but not SH3-mutated Abl or v-Abl. When transfected in NIH-3T3 cells, Pag is localized to nucleus and cytoplasm and rescues the cytostatic effect induced by c-Abl. These observations suggest Pag is a physiological inhibitor of c-Abl in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9334312      PMCID: PMC316562          DOI: 10.1101/gad.11.19.2456

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  73 in total

1.  Antisense RNA of the latent period gene (MER5) inhibits the differentiation of murine erythroleukemia cells.

Authors:  Y Nemoto; T Yamamoto; S Takada; Y Matsui; M Obinata
Journal:  Gene       Date:  1990-07-16       Impact factor: 3.688

2.  Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src.

Authors:  H Hirai; H E Varmus
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

3.  The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization.

Authors:  R A Van Etten; P Jackson; D Baltimore
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

4.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

5.  Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene.

Authors:  V L Tybulewicz; C E Crawford; P K Jackson; R T Bronson; R C Mulligan
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

6.  Cloning of a housekeeping-type gene (MER5) preferentially expressed in murine erythroleukemia cells.

Authors:  T Yamamoto; Y Matsui; S Natori; M Obinata
Journal:  Gene       Date:  1989-08-15       Impact factor: 3.688

7.  Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor.

Authors:  A M Pendergast; A J Muller; M H Havlik; R Clark; F McCormick; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

8.  Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity.

Authors:  E T Kipreos; J Y Wang
Journal:  Science       Date:  1990-04-13       Impact factor: 47.728

9.  Mutations in src homology regions 2 and 3 of activated chicken c-src that result in preferential transformation of mouse or chicken cells.

Authors:  H Hirai; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

10.  Evidence that the Abelson virus protein functions in vivo as a protein kinase that phosphorylates tyrosine.

Authors:  B M Sefton; T Hunter; W C Raschke
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

View more
  74 in total

1.  The kinase-deficient Src acts as a suppressor of the Abl kinase for Cbl phosphorylation.

Authors:  T Shishido; T Akagi; T Ouchi; M M Georgescu; W Y Langdon; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Two distinct phosphorylation pathways have additive effects on Abl family kinase activation.

Authors:  Keith Q Tanis; Darren Veach; Henry S Duewel; William G Bornmann; Anthony J Koleske
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 3.  Epigenetic regulation of peroxiredoxins: Implications in the pathogenesis of cancer.

Authors:  Suet-Hui Ow; Pei-Jou Chua; Boon-Huat Bay
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

4.  N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor.

Authors:  Yongmun Choi; Markus A Seeliger; Shoghag B Panjarian; Hakjoong Kim; Xianming Deng; Taebo Sim; Brian Couch; Anthony J Koleske; Thomas E Smithgall; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-08-13       Impact factor: 5.157

5.  Identification of differentially regulated secretome components during skeletal myogenesis.

Authors:  C Y X'avia Chan; Olena Masui; Olga Krakovska; Vladimir E Belozerov; Sebastien Voisin; Shaun Ghanny; Jian Chen; Dharsee Moyez; Peihong Zhu; Kenneth R Evans; John C McDermott; K W Michael Siu
Journal:  Mol Cell Proteomics       Date:  2011-02-22       Impact factor: 5.911

6.  Activation of abl family kinases in solid tumors.

Authors:  Sourik S Ganguly; Rina Plattner
Journal:  Genes Cancer       Date:  2012-05

Review 7.  Signaling functions of reactive oxygen species.

Authors:  Henry Jay Forman; Matilde Maiorino; Fulvio Ursini
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

Review 8.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

9.  ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.

Authors:  Jinghe Li; Zhu-Lin Yang; Xuebao Ren; Qiong Zou; Yuan Yuan; Lufeng Liang; Meigui Chen; Senlin Chen
Journal:  Tumour Biol       Date:  2012-10-13

10.  Human peroxiredoxin PrxI is an orthologue of yeast Tsa1, capable of suppressing genome instability in Saccharomyces cerevisiae.

Authors:  Ismail Iraqui; Gérard Faye; Sandrine Ragu; Amélie Masurel-Heneman; Richard D Kolodner; Meng-Er Huang
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.